Vanda Pharmaceuticals wins European orphan designation for imsidolimab
Vanda Pharmaceuticals (VNDA) says the European Commission granted orphan designation to imsidolimab for the treatment of generalized pustular psoriasis.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.